BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

664 related articles for article (PubMed ID: 26910912)

  • 1. MicroRNA-410 acts as oncogene in NSCLC through downregulating SLC34A2 via activating Wnt/β-catenin pathway.
    Zhang X; Ke X; Pu Q; Yuan Y; Yang W; Luo X; Jiang Q; Hu X; Gong Y; Tang K; Su X; Liu L; Zhu W; Wei Y
    Oncotarget; 2016 Mar; 7(12):14569-85. PubMed ID: 26910912
    [TBL] [Abstract][Full Text] [Related]  

  • 2. microRNA-100 functions as a tumor suppressor in non-small cell lung cancer via regulating epithelial-mesenchymal transition and Wnt/β-catenin by targeting HOXA1.
    Han W; Ren X; Yang Y; Li H; Zhao L; Lin Z
    Thorac Cancer; 2020 Jun; 11(6):1679-1688. PubMed ID: 32364673
    [TBL] [Abstract][Full Text] [Related]  

  • 3. miR-367 promotes tumor growth by inhibiting FBXW7 in NSCLC.
    Xiao G; Gao X; Sun X; Yang C; Zhang B; Sun R; Huang G; Li X; Liu J; Du N; Liu D; Liang R; Ren H; Qin S
    Oncol Rep; 2017 Aug; 38(2):1190-1198. PubMed ID: 28656290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MiR-770 inhibits tumorigenesis and EMT by targeting JMJD6 and regulating WNT/β-catenin pathway in non-small cell lung cancer.
    Zhang Z; Yang Y; Zhang X
    Life Sci; 2017 Nov; 188():163-171. PubMed ID: 28882645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TRIM47 overexpression is a poor prognostic factor and contributes to carcinogenesis in non-small cell lung carcinoma.
    Han Y; Tian H; Chen P; Lin Q
    Oncotarget; 2017 Apr; 8(14):22730-22740. PubMed ID: 28186994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MiR-503 targets PI3K p85 and IKK-β and suppresses progression of non-small cell lung cancer.
    Yang Y; Liu L; Zhang Y; Guan H; Wu J; Zhu X; Yuan J; Li M
    Int J Cancer; 2014 Oct; 135(7):1531-42. PubMed ID: 24550137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects and mechanisms of SLC34A2 on tumorigenicity in human non-small cell lung cancer stem cells.
    Jiang Z; Hao Y; Ding X; Zhang Z; Liu P; Wei X; Xi J
    Tumour Biol; 2016 Aug; 37(8):10383-92. PubMed ID: 26846105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MicroRNA-92a promotes epithelial-mesenchymal transition through activation of PTEN/PI3K/AKT signaling pathway in non-small cell lung cancer metastasis.
    Lu C; Shan Z; Hong J; Yang L
    Int J Oncol; 2017 Jul; 51(1):235-244. PubMed ID: 28534966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between downexpression of MiR-203 and poor prognosis in non-small cell lung cancer patients.
    Tang R; Zhong T; Dang Y; Zhang X; Li P; Chen G
    Clin Transl Oncol; 2016 Apr; 18(4):360-8. PubMed ID: 26307752
    [TBL] [Abstract][Full Text] [Related]  

  • 10. lncRNA JPX/miR-33a-5p/Twist1 axis regulates tumorigenesis and metastasis of lung cancer by activating Wnt/β-catenin signaling.
    Pan J; Fang S; Tian H; Zhou C; Zhao X; Tian H; He J; Shen W; Meng X; Jin X; Gong Z
    Mol Cancer; 2020 Jan; 19(1):9. PubMed ID: 31941509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TUG1 knockdown inhibits the tumorigenesis and progression of prostate cancer by regulating microRNA-496/Wnt/β-catenin pathway.
    Li G; Yang J; Chong T; Huang Y; Liu Y; Li H
    Anticancer Drugs; 2020 Jul; 31(6):592-600. PubMed ID: 32427740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MTA1 promotes epithelial to mesenchymal transition and metastasis in non-small-cell lung cancer.
    Ma K; Fan Y; Dong X; Dong D; Guo Y; Wei X; Ning J; Geng Q; Wang C; Hu Y; Li M; Niu W; Li E; Wu Y
    Oncotarget; 2017 Jun; 8(24):38825-38840. PubMed ID: 28418915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Downregulation of the TGFβ Pseudoreceptor BAMBI in Non-Small Cell Lung Cancer Enhances TGFβ Signaling and Invasion.
    Marwitz S; Depner S; Dvornikov D; Merkle R; Szczygieł M; Müller-Decker K; Lucarelli P; Wäsch M; Mairbäurl H; Rabe KF; Kugler C; Vollmer E; Reck M; Scheufele S; Kröger M; Ammerpohl O; Siebert R; Goldmann T; Klingmüller U
    Cancer Res; 2016 Jul; 76(13):3785-801. PubMed ID: 27197161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Knockdown of Nemo‑like kinase promotes metastasis in non‑small‑cell lung cancer.
    Shi C; Xu L; Tang Z; Zhang W; Wei Y; Ni J; Zhang S; Feng J
    Oncol Rep; 2019 Sep; 42(3):1090-1100. PubMed ID: 31322229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Upregulated lncRNA SNHG1 contributes to progression of non-small cell lung cancer through inhibition of miR-101-3p and activation of Wnt/β-catenin signaling pathway.
    Cui Y; Zhang F; Zhu C; Geng L; Tian T; Liu H
    Oncotarget; 2017 Mar; 8(11):17785-17794. PubMed ID: 28147312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Downregulation of miR-3127-5p promotes epithelial-mesenchymal transition via FZD4 regulation of Wnt/β-catenin signaling in non-small-cell lung cancer.
    Yang Y; Sun Y; Wu Y; Tang D; Ding X; Xu W; Su B; Gao W
    Mol Carcinog; 2018 Jul; 57(7):842-853. PubMed ID: 29566281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MiR-200c/FUT4 axis prevents the proliferation of colon cancer cells by downregulating the Wnt/β-catenin pathway.
    Cong J; Gong J; Yang C; Xia Z; Zhang H
    BMC Cancer; 2021 Jan; 21(1):2. PubMed ID: 33397320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Forced overexpression of FBP1 inhibits proliferation and metastasis in cholangiocarcinoma cells via Wnt/β-catenin pathway.
    Zhao W; Yang S; Chen J; Zhao J; Dong J
    Life Sci; 2018 Oct; 210():224-234. PubMed ID: 30193944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hsa-miR-326 targets CCND1 and inhibits non-small cell lung cancer development.
    Sun C; Huang C; Li S; Yang C; Xi Y; Wang L; Zhang F; Fu Y; Li D
    Oncotarget; 2016 Feb; 7(7):8341-59. PubMed ID: 26840018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circ_0067934 promotes non-small cell lung cancer development by regulating miR-1182/KLF8 axis and activating Wnt/β-catenin pathway.
    Zhao M; Ma W; Ma C
    Biomed Pharmacother; 2020 Sep; 129():110461. PubMed ID: 32768951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.